medigraphic.com

2003, Number 4

<< Back Next >>

Enf Infec Microbiol 2003; 23 (4)

Measles.Current concepts

Wong CRM

Language: Spanish
References: 25
Page: 133-136
PDF size: 53.57 Kb.


ABSTRACT

Measles is an exanthematous illness caused by a Paramyxaviridae, it is highly contagious. The virus is transmitted by transfer of nasopharyngeal secretions to the respiratory mucous membranes or conjuntivas of susceptible individuals, the more frequent complication is pneumonia. Before vaccination was available, epidemics occurred in children, usually by spring, now it appears in teenagers and young adults. An optimal coverage exceeding 95% is desirable. Measles vaccine given by aerosol can be a good alternative for mass vaccination, for children less than 1 year old and as a booster, not only because of the lower risk of complications but because of good levels of immunization.


REFERENCES

  1. Feigin RD, Cherry JD. Textbook of Pediatric Infectious Diseases. Ed WB Saunders Company. 4a. edición, 1998:2054-2074.

  2. Santos José Ignacio. El Programa Nacional de Vacunación: orgullo de México. Rev Fac Med UNAM 2002;45(3):142-153.

  3. World Health Organization. Measles control in the 1990’s: planof action for global measles control. WHO/EPI/GEN 1992:3.

  4. World Health Organization. Global measles mortality reduction and regional elimination. WHO Weekly epidemiological record. 2002;77(7):49-56.

  5. Aaby P, Clements J, Orinda V. Mortality from measles: measuring the impact. In Expanded Programme on Immunization. W. H. Organization, ed, Geneva. 1991.

  6. Aaby P, Bukh J, Kronborg D, Lisse IM, da Silva MC. Delayed excess mortality after exposure to measles during the first six months of life. Am J Epidemiol 1990;132:211-9.

  7. Clements CJ, Cutts FT. The epidemiology of measles: thirty years of vaccination. Curr Top Microbiol Immunol 1995;191:13-33.

  8. Cherry JD. Measles. 1992, Saunders, Philadelphia.

  9. Nokes DJ, Anderson RM. Measles, mumps and rubella vaccine: what coverage to block transmission? Lancet 1988;2:1374.

  10. Centers for Disease Control and Prevention. Measles Eradication: Recommendations from a Meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. MMWR 1997;46(RR-11):1-20.

  11. Fernández de Castro J, Kumate J. La vacunación contra el sarampión. Situación en México y América. Avances en el método de inmunización por aerosol. Bol Med Hosp Infant Mex 1990;47(7):449-461.

  12. Casos de notificación inmediata y semanal. Boletín de Epidemiología. Sistema Nacional de Vigilancia Epidemiológica. EPIDEMIOLOGÍA. 2-8 Octubre, 2003.

  13. Cutts FT, Steinglass R. Should measles be eradicated? BMJ 1998;316(7133):765-767.

  14. Cutts FT, Henao-Restrepo AM, Olivé JM. Measles elimination: progress and challenges. Vaccine 1999;17:S47-S52.

  15. Pan American Health Organization. Measles in the Americas, 1998. EPI Newsletter. 1998;20(6):1-2.

  16. Pan American Health Organization. Measles outbreak in Nuble Province, Chile. EPI Newsletter 1998;20(3):2-3.

  17. Cutts FT, Olivé JM. Vaccination programs in developing countries. In: Plotkin SA, Orenstein WA, editors. Vaccines, 3rd ed. Philadelphia: W.B. Saunders 1998;44:1047-73

  18. Nokes D, Cutts F. Immunization in the developing world: strategic challenges. Transactions of the Royal Society of Tropical Medicine and Hygiene 1993;87:353-354.

  19. UNICEF WHO. State of the world´s vaccines and immunization. Geneva: World Health Organization, 1996.

  20. Cutts FT, Clements CJ, Bennet JV. Alternative routes of measles immunization: a review. Biologicals 1997;25:323-8.

  21. Wong-Chew RM, Islas-Romero R, García-García ML, Beeler J, Audet S, Santos-Preciado JI, Gans H, Lew-Yasukawa L, Maldonado Y, Arvin A, Valdespino-Gómez JL. Induction of Cellular and Humoral Immunity After Aerosol or Subcutaneous Administration of Edmonston-Zagreb Measles Vaccine as a Primary Dose to 12 Month Old Children. Journal of Infectious Diseases. En prensa.

  22. Dilraj A, Cutts F, Fernandez de Castro J, Wheeler J, Brown D, Roth C, Coovadia H, Bennett J. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomized trial. Lancet 2000;355:798-803.

  23. Sepulveda-Amor J, Valdespino-Gómez JL, García-García ML, Bennet J, Islas-Romero R, Echaniz-Aviles G, Fernández de Castro J. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 2002;20:2790-2795.

  24. LiCalsi C, Maniaci J, Christensen T, Phillips E, Ward G, Witham C. A powder formulation of measles vaccine for aerosol delivery. Vaccine 2001;19:2629-2636.

  25. LiCalsi C, Christensen T, Bennet JV, Phillips E, Witham C. Dry powder inhalation as a potential delivery method for vaccines. Vaccine 1999;17:1796-1803.




2020     |     www.medigraphic.com